Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Core Viewpoint - Aeterna Zentaris Inc. has completed its Phase 3 DETECT-trial for macimorelin, aimed at diagnosing Childhood Onset Growth Hormone Deficiency (CGHD), and expects to report top-line data in Q3 2024 [1][2][3] Company Overview - Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing a diverse portfolio of pharmaceutical and diagnostic products, including macimorelin for growth hormone deficiency [1][7] - Macimorelin is the first and only FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency (AGHD) [5][7] Clinical Trial Details - The DETECT-trial is a multicenter, open-label study that enrolled 100 subjects across Europe and North America to evaluate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test in pediatric patients [2][3] - The trial's completion is a significant milestone, expanding the market for macimorelin in endocrinology and providing a diagnostic tool for children [3] Future Expectations - The company anticipates presenting top-line data and full study results from the DETECT-trial in the third quarter of 2024 [1][3]